Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 7, 2016; 22(37): 8271-8282
Published online Oct 7, 2016. doi: 10.3748/wjg.v22.i37.8271
Published online Oct 7, 2016. doi: 10.3748/wjg.v22.i37.8271
Marker | Cut-off1 | Sensitivity | Specificity | Detection method (most reliable) | Ref. |
AFP | 7.7-112.0 ng/mL | 25%-90% | 87%-97% | ELISA | [36,73] |
AFP-l3 | 3%-20% | 36%-96% | 89%-94% | Liquid-Phase Binding Assay | [46,47,52] |
DCP | 40-150 mAU/mL | 44%-91% | 68%-99% | Electrochemiluminescence immunoassay | [36,53] |
Osteopontin | 9.3-642.5 ng/mL | 73%-97% | 55%-100% | ELISA | [65] |
GP73 | 78-150 ng/mL | 68%-95% | 9%-97% | Immunoblotting, Western Blotting or ELISA2 | [36,71,72] |
GPC-3 | 2-300 ng/mL | 36%-100% | 40%-100% | ELISA | [36,78] |
SCCA | 0.12-3.80 ng/mL | 42%-80% | 50%-88% | ELISA | [36,81] |
DKK1 | 1.01-2.15 ng/mL | 69%-91% | 62%-91% | ELISA | [86-88] |
miRNA-21 | NA | 84%-90% | 71%-92% | qRT-PCR | [83] |
miRNA-122 | NA | 70%-82% | 69%-84% | qRT-PCR | [83] |
- Citation: Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol 2016; 22(37): 8271-8282
- URL: https://www.wjgnet.com/1007-9327/full/v22/i37/8271.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i37.8271